Results 131 to 140 of about 13,388,853 (301)

Funnel plot for mean difference (MD) in the change in HbA1c (DPP-4 inhibitor vs. placebo or no treatment).

, 2014
Funnel plot for mean difference (MD) in the change in HbA1c (DPP-4 inhibitor vs. placebo or no treatment).
Dongsheng Cheng (652883), Xiaoxia Wang (14667), Junhui Li (304434), Yumei Liu (286628), Yuqiang Chen (652884), Niansong Wang (304438), Yang Fei (504329)   +6 more
core   +1 more source

Positive modulation of glucagon‐like peptide 1 (GLP‐1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes

British Journal of Pharmacology, EarlyView.
Haemorphins act on GLP‐1 receptor (GLP‐1R) activity and signalling in a positive allosteric manner. This leads to potentiated GLP‐1‐mediated activity and signalling, as well as insulin synthesis, which may have implications for glucose metabolism and, thereby, diabetes and obesity. (The graph was created in BioRender.com).
Farheen Badrealam Khan, Rwdah Mohamed Alameri, Yasir S. Raouf, Damien Maurel, Naiem Ahmad Wani, Anatoliy Shmygol, Irfa Anwar, Heng B. See, Elizabeth K. M. Johnstone, Elodie Dupuis, Eric Trinquet, Kevin D. G. Pfleger, Emilia Oueis, Mohammed Akli Ayoub   +13 more
wiley   +1 more source

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

, 2009
Type 2 diabetes mellitus (T2DM) is a global epidemic with increasing impact on individuals and healthcare providers. Available treatments (such as metformin, sulfonylureas, glitazones, and insulin) have proven unsatisfactory in producing a long-lasting ...
Piya, Milan K, Piya, Milan, Piya, Milan K. (R19111), Barnett, Anthony, R. Keith Campbell, Barnett, Anthony H., Tahrani, Abd A., Tahrani, Abd; id_orcid, Joshua J. Neumiller, Barnett, Anthony H, Tahrani, Abd A   +10 more
core   +1 more source

The E‐cadherin‐Wnt‐mir‐994 Axis Repurposes a Cadherin Switch for Niche Robustness and Germline Stem Cell Maintenance

Cell Proliferation, EarlyView.
In the Drosophila ovarian niche, an E‐cadherin‐to‐N‐cadherin switch, mediated by Wnt‐mir‐994 signalling, is repurposed to ensure niche resilience. This compensatory mechanism maintains niche integrity and stem cell support upon E‐cadherin loss, revealing a robustness circuit.
Renjun Tu, Hiu Laam Yau, Runzhi Deng, Sarah E. Webb, Shiyuan Chen, Jianquan Ni, Ting Xie   +6 more
wiley   +1 more source

DPP-4 inhibitor [PDF]

, 2020
openaire   +1 more source

The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska, Ryan Chung, Salman Ramjaun, Danyao Jin, Ciara Doherty, Kieran McCafferty, Samuel Seidu   +6 more
wiley   +1 more source

Drugs for diabetes: part 5 DPP-4 inhibitors

, 2011
The dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral drugs for the treatment of type 2 diabetes. They inhibit the breakdown of glucagon-like peptide-1 (GLP-1) and increase the incretin effect in patients with type 2 diabetes. In clinical
Fisher, Miles, McKay, Gerard A., McDougall, Claire   +2 more
core  

Surface Energy Modification of Semi-Random P3HTT-DPP

, 2016
Alkyl solubilizing side chains on conjugated polymers can serve as a handle for modifying polymer properties. Recently, oligo-ether and semifluoro alkyl side chains were utilized to tune the surface energy of random P3HT-based polymers without changing ...
Sangtaik Noh (1565080), Seyma Ekiz (2901596), Jenna B. Howard (1565083), Barry C. Thompson (1565077)   +3 more
core   +1 more source

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim, Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon‐Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim, Bong‐Soo Cha   +14 more
wiley   +1 more source

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice. [PDF]

Biomedicines, 2023
Alshamrani AA, Al-Hamamah MA, Albekairi NA, Attia MSM, Ahmad SF, Assiri MA, Ansari MA, Nadeem A, Bakheet SA, Alanazi WA, Attia SM.   +10 more
europepmc   +1 more source